pirbuterol (Discontinued)

Brand and Other Names:Maxair
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

metered dose inhaler

  • 200mcg/actuation (14g canister; ~400 actuations)

Asthma Maintenance Treatment

1-2 actuations q4-6hr PRN; not to exceed 12 actuations/day

CFC-propelled MDIs are being phased out; Maxair will not be manufactured, sold, or dispensed in the US after 12/31/13

Dosage Forms & Strengths

metered dose inhaler

  • 200mcg/actuation (14g canister; ~400 actuations)

Asthma Maintenance Treatment

<12 years: Safety and efficacy not established

>12 years: As adults; 1-2 actuations q4-6hr PRN; not to exceed 12 actuations/day

CFC-propelled MDIs are being phased out; Maxair will not be manufactured, sold, or dispensed in the US after 12/31/13

Next:

Interactions

Interaction Checker

and pirbuterol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Nervousness

            Restlessness

            Serum glucose increased

            Serum potassium decreased

            Trembling

            Palpitations

            Tachycardia

            CoughHeadache

            Dizziness

            Lightheadedness

            Taste changes

            Vomiting

            Nausea

            Paradoxical bronchospasm

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Risk of hypokalemia, usually transient

            Metered-dose inhalers that contain chlorofluorocarbons (CFCs) are currently being phased out in the United States; alternate inhalers without CFCs are available

            Use caution in cardiovascular disease, glaucoma, hyperthyroidism, hypokalemia, and seizure disorders

            May increase serum glucose; use caution in diabetes mellitus

            Fatal outcomes reported with excessive use of therapy

            Not for use in chronic asthma therapy unless anti-inflammatory agent use concomitantly

            Paradoxical bronchospasm may occur with therapy

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Not known if excreted in breast milk; not recommended

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Beta-2 receptor agonist with some beta-1 activity

            Pharmacokinetics

            Half-Life: 2 hr

            Onset: <5 min; 0.5-1 hr (peak effect)

            Duration: 5 hr

            Metabolism: Hepatic

            Excretion: Urine (10%)

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.